|
⚲
|
| Keyboard |
| Bridger Management LLC
✚
|
|
|---|---|
| CRD # | 160738 |
| SEC # | 801-74245 |
| CIK # | 0001166309 |
| AUM | 485.2 M (2026-03-27) |
| Employees | 8 (62% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-984-2125 |
| Address | 90 Park Avenue 40th Fl New York, NY 10016 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Asset-Based and Performance-Based Compensation The fees and compensation applicable to each of the Funds are set forth in detail in the corresponding Offering Documents. A brief summary of the fees and compensation applicable to the Funds is provided below. We receive from the Swiftcurrent Fund a quarterly management fee (the “Management Fee”), which ranges from 1.5% to 2.0% per annum of the net asset value of a Fund and is paid from the assets of the Swiftcurrent Fund quarterly in advance, and an allocable portion of the Management Fee is deducted from each relevant investor’s account at the beginning of the relevant accounting period. In the case of an investor admitted to a Fund after the first business day of the relevant calendar quarter, the Management Fee is pro-rated based on the admission date of such investor. Effective as of January 1, 2023, Bridger has waived all future Management Fees for the Healthcare Fund. Management Fees assessed on investments in pooled investment vehicles by Bridger, its affiliates their principals, members of the immediate families of such persons or trusts or other entities for their benefit are reduced or waived entirely. Generally, a Fund will pay the Management Fee in advance. If the investment management agreement is terminated before the end of the billing period, Bridger will refund a pro rata portion of the pre-paid fee to the Fund’s investors. The Auson Fund is not charged any Management Fees. An affiliate of Bridger is entitled to an incentive allocation (the “Incentive Allocation”) from the Swiftcurrent Fund equal to 20% of any net profit allocable to each investor for such fiscal year in excess of any loss recovery with respect to such investor’s account, adjusted for contributions, withdrawals and distributions. The Incentive Allocation will be allocated as of the close of each fiscal year and on any interim redemption or withdrawal of capital by an investor. Bridger Management, LLC Form ADV Part 2A Brochure Effective as of January 1, 2023, an affiliate of Bridger waived its entitlement to receive any future Incentive Allocation from the Healthcare Fund. Incentive Allocation assessed on investments in pooled investment vehicles by Bridger, its affiliates, their principals, members of the immediate families of such persons or trusts or other entities for their benefit are reduced or waived entirely. The Auson Fund is not subject to any Incentive Allocation. Other Expenses The Funds bear their own costs and expenses, such as administrative expenses, investment expenses (e.g., brokerage commissions and expenses of outsourced trading desks, and interest expense), fees and expenses of their governing bodies, legal expenses, valuation, accounting (including without limitation the fees and expenses of any administrator retained for the Funds and the fees and expenses related to regulatory filings of the Funds, the general partner/managing member and Bridger that relate to the Funds (including by way of illustration, Form PF)), auditing and tax preparation expenses, taxes, expenses relating to the offer and sale of interests in the Funds, expenses relating to the organization of the Funds and extraordinary expenses. To the extent the Funds invest in exchange traded funds and/or private investment funds, the Funds would be subject to additional fees and expenses payable by such funds. Costs and expenses common to one or more Clients are generally paid pro rata by each Client based on net asset value, invested capital, the allocation of related time and services, or such other equitable basis as determined in the discretion of Bridger. If Client account assets are invested in a master-feeder structure, the feeder funds bear a pro rata share of the expenses associated with the related master fund. The expenses incurred in connection with a transaction that is consummated will generally be allocated among Funds and any participating third-party investors pro rata in accordance with their respective actual investments or commitments in such investment opportunity, unless Bridger determines that a different allocation methodology would be more equitable. Any expenses incurred in connection with a transaction that is not consummated will generally be allocated among the expected participants in the investment pro rata in accordance with their respective expected investment or commitment in such unconsummated investment opportunity. The Clients incur brokerage and other transaction costs when brokers are used in connection with their investments. For additional information regarding brokerage practices, please see Item 12 below. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 7: Types of Clients Bridger provides investment advisory services to the Clients. Investment advice is provided directly to the Funds, subject to the discretion and control of the general partner/managing member or the board of directors of the applicable Fund, and not individually to the investors in the Funds. Interests in the Funds are offered pursuant to applicable exemptions from registration under the 1940 Act and the Securities Act. Investors in the Funds may include high net worth individuals, trusts, estates, charitable organizations, endowments, corporations, limited partnerships, limited liability companies, pension funds, and similar entities. With respect to a Client that is a pooled investment vehicle, any initial and additional subscription minimums are disclosed in the Offering Documents for the pooled investment vehicle. Bridger does not have any standard requirements for opening or maintaining a separately managed account and may, in its discretion, require a different minimum for any Client account. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Morgan Stanley | 0.0 | ||
| Amazon Com Inc | 0.0 | ||
| Teva Pharmaceutical Industries Ltd | 0.0 | ||
| Stars Group Inc | 0.0 | ||
| Dexcom Inc | 0.0 | ||
| Alcon Inc | 0.0 | ||
| Nike Inc | 0.0 | ||
| Alphabet Inc | 0.0 | ||
| Visa Inc | 0.0 | ||
| Churchill Downs Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Bridger Healthcare SIV I LP | [2022-02-25] | 17.5 M | 1.4 M |
| Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Bridger Healthcare SIV I LP | 2021-11-29 | 17.5 M | |
| HF | Swiftcurrent Master Fund Ltd | [2021-11-29] | 1,371.3 M | 297.6 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Auson Holdings LLC | [2018-10-08] | 76.8 M | 125.3 M |
| Filed 2025-07-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Bridger Healthcare Ltd | [2014-11-28] | 235.0 M | 0.3 M |
| Filed 2023-06-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Swiftcurrent Offshore Master Ltd | [2014-03-31] | 2,337.8 M | 523.0 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | ALEA Partners LLC | 2012-02-15 | 10.0 M | |
| PE | Bridger Horizon Vietnam Partners LP | [2012-02-15] | 1.1 M | |
| Other | North Forty Partners LLC | 2012-02-15 | 28.9 M | |
| HF | Swiftcurrent Offshore Ltd | [2012-02-15] | 2,337.8 M | 1,610.2 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 0.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 0.5 |
| By Discretionary | ||
| Discretionary | 3 | 0.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 0.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.4 | |
| United States Persons | 0.1 | |
| Total | 3 | 0.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Robert Meschi | Director | 145 | 22 | |
| Brian Eden | Director | 36 | 15 | |
| Lucas Warford | Executive Officer | 8 | 3 | |
| Neil Cammarosano | Director, Executive Officer | 7 | 3 | |
| Bridger Management LLC | Promoter | 7 | 2 | |
| Roberto Mignone | Executive Officer, Promoter | 6 | 2 | |
| Michael Tierney | Executive Officer | 4 | 2 | |
| Blake Goodner | Promoter | 3 | 2 | |
| Matthew Truax | Director, Executive Officer | 3 | 1 | |
| Bridger Capital LLC | Executive Officer | 2 | 1 | |
| Bridger Healthcare Holdings GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001166309] | |
| 3 | [0001166309] | |
| 4 | [0001166309] | |
| SC 13D | [0001166309] | |
| SC 13G | [0001166309] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $2.8B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | JM1U681K2Z42HG324E45 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2016-11-11 | Buy | 322,472 | $3.08 | 993,214 |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-18 | Disposed to issuer | 2,841,255 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-18 | Disposed to issuer | 1,793,745 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-17 | Disposed to issuer | 147,060 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-17 | Disposed to issuer | 232,940 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-16 | Disposed to issuer | 183,905 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-16 | Disposed to issuer | 116,095 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-13 | Disposed to issuer | 47,900 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-13 | Disposed to issuer | 547,100 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-11 | Disposed to issuer | 30,000 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-10 | Disposed to issuer | 60,000 | $0.00 | |
|
Cardiff Oncology Inc TROV
Common Stock, $0.0001 par value per share
|
2015-07-17 | Buy | 140,000 | $8.75 | 1,225,000 |
|
Response Genetics Inc RGDX
Warrants (right to buy) · derivative
|
2015-04-03 | Other | 1,351,352 | ||
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-04-02 | Buy | 300,000 | $6.90 | 2,070,000 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-27 | Buy | 79,343 | $5.62 | 445,908 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-26 | Buy | 78,801 | $5.42 | 427,101 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-25 | Buy | 105,142 | $5.12 | 538,327 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-06 | Buy | 444,444 | $4.50 | 1,999,998 |
|
Response Genetics Inc RGDX
Common Stock, par value $.01 per share
|
2012-09-13 | Buy | 3,000,000 | $1.10 | 3,300,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Endowment Advisers LP
✚
|
TX | 499.7 M |
|
Riposte Capital LLC
✚
|
NY | 496.6 M |
|
Basin Oil and Gas Management LP
✚
|
TX | 492.7 M |
|
OnyxPoint Global Management LP
✚
|
NY | 481.2 M |
|
Lion Point Capital LP
✚
|
NY | 480.6 M |
|
JW Asset Management LLC
✚
|
476.9 M | |
|
Sycale Advisors NY LLC
✚
|
NY | 473.1 M |
|
AOF Management LLC
✚
|
CA | 461.5 M |
|
Saybrook Fund Advisors LLC
✚
|
CA | 461.2 M |
|
Harspring Capital Management LLC
✚
|
NY | 459.1 M |